KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Short term Debt (2018 - 2021)

Twist Bioscience has reported Short term Debt over the past 4 years, most recently at $9.1 million for Q4 2021.

  • Quarterly Short term Debt rose 172.49% to $9.1 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2021, up 172.49% year-over-year, with the annual reading at $1.6 million for FY2021, 53.44% down from the prior year.
  • Short term Debt was $9.1 million for Q4 2021 at Twist Bioscience, up from $1.6 million in the prior quarter.
  • Over five years, Short term Debt peaked at $9.1 million in Q4 2021 and troughed at $1.6 million in Q3 2021.
  • The 4-year median for Short term Debt is $3.3 million (2018), against an average of $3.5 million.
  • The largest YoY upside for Short term Debt was 172.49% in 2021 against a maximum downside of 53.44% in 2021.
  • A 4-year view of Short term Debt shows it stood at $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019, then changed by 0.0% to $3.3 million in 2020, then skyrocketed by 172.49% to $9.1 million in 2021.
  • Per Business Quant, the three most recent readings for TWST's Short term Debt are $9.1 million (Q4 2021), $1.6 million (Q3 2021), and $2.4 million (Q2 2021).